Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)

NCT05931393 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

RCC
Renal Cell Carcinoma

Interventions

DRUG: Cabozantinib 80 MG

Sponsor

University of Texas Southwestern Medical Center

Collaborators

[object Object]